Moreover, the CFTR modulators Ivacaftor/Lumacaftor and Ivacaftor/Tezacaftor showed a powerful anti-inflammatory effect in patients with CF, reducing the levels of IL-18, and both IL-1β and IL-18, correspondingly, in monocytes and serum of patients with CF [177]. This evidence concerns the gene IL1B and cystic fibrosis.